Rutgers Expert Available to Discuss Recent Expanded HPV Vaccine Mid-Adult Indication And Policies Surrounding Decision
Rutgers scholar Mark Einstein, MD is available to comment on the FDA’s approval of a vaccine, known as Gardasil 9, for people ages 27 to 45 to prevent the human papillomavirus (HPV) and cervical cancer. The vaccine had previously been approved for minors and people up to age 26.
Einstein, professor and chair of the Department of Obstetrics, Gynecology, and Women’s Health at Rutgers New Jersey Medical School, said the United States has low rates of vaccination against HPV-associated cancers when compared to other developed countries in the world.
“This is a cancer-prevention vaccine,” said Einstein. “Everyone has HPV, but very few people get any clinically relevant disease. While it is best to give this vaccine to younger people, this vaccine works even if there has been prior HPV exposure for other HPV types.”
Einstein said women have a higher rate of HPV than men, but the vaccine works effectively in both genders to prevent HPV associated diseases.
Einstein, a consultant to the World Health Organization on the immune basis for HPV vaccination, is available to discuss the FDA’s approval as well as policies, cancer prevention and burden of disease surrounding HPV.
Media interested in interviewing Einstein can contact Tiffany Cody at (973) 972-3501 (o); (973) 856-0517 (c); or [email protected].
RSS